Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Roche licenses IPF candidate to Ark Biosciences

Executive Summary

Roche’s Genentech Inc. licensed Ark Biosciences Inc. exclusive worldwide development and commercialization rights to its Phase I idiopathic pulmonary fibrosis (IPF) program AK3280 (GDC3280) plus related compounds.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Reverse Licensing
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register